You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. SWIFT ActiveScreener research and development of an intelligent web based document screening system

    SBC: Sciome LLC            Topic: NIEHS

    Project Summary More than systematic reviews are performed each year in the fields of environmental health and evidence based medicine with each review requiring on average between six months to one year of effort to complete In order to remain accurate systematic reviews require regular updates after their initial publication with most reviews out of date within five years In the sc ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Clinical evaluation of the novel uni directional Pd CivaSheet for Lung Cancer

    SBC: CIVATECH ONCOLOGY INC            Topic: 102

    CivaTech Oncology s mission is to provide improved radiation therapy directly to localized tumors The Company has developed a novel polymer encapsulated membrane like radiation source that emits radiation on only one side of the device the CivaSheet This directional source is compatible with open and minimally invasive surgical techniques and has FDA clearance to be used as primary or combin ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Tuned stem cell extracellular vesicles as a novel chronic wound therapeutic

    SBC: Zen-Bio, Inc.            Topic: NIA

    Project Summary The elderly population is rapidly increasing worldwide and those over years old are expected to comprise of the total population by These demographic changes will focus healthcare needs on those conditions more prevalent in the elderly Chronic wounds such as venous leg ulcers pressure ulcers and diabetic ulcers are over represented in the elderly population and even ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. An optimized NK2R agonist for 'on-demand' voiding

    SBC: Dignify Therapeutics LLC            Topic: NIA

    PROJECT SUMMARY Underactive bladderUABis a clinically important problem in the elderlyUAB is characterized by weak bladder contractions and incomplete bladder emptying that result in symptoms of voiding frequencynocturiaand incontinenceand it can lead to serious complications such as permanent bladder and kidney damageAging related UAB may affect almostof Americans overand nearly two thirds of inc ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Discovering a Disease Modifying Therapeutic to Treat Huntington's Disease

    SBC: CHAPERONE THERAPEUTICS, INC.            Topic: NIA

    Protein misfolding and aggregationleading to chronic inflammationsynaptic dysfunction and neuronal death are common hallmarks of neurodegenerative diseases including Alzheimer s diseaseADand Huntington s diseaseHDWhile overmillion Americans suffer from ADand oversuffer from HDcurrent therapies target symptoms but not the underlying pathophysiology of protein misfoldingaggregation and its downstrea ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Validation of a Performance Based Measure of Functioning in MCI and Early AD

    SBC: NEUROCOG TRIALS            Topic: NIA

    Project Summary Alzheimer s disease AD is expected to rise in prevalence from to million Americans by leading to of deaths among adults over This epidemic is projected to overwhelm healthcare and economic resources with costs reaching $ billion in the US in and $ trillion by There is no cure for AD and no new drugs have been successful in treating the advance ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Functional Tissue Engineering for Cartilage Repair

    SBC: Cytex Therapeutics, Inc.            Topic: NIA

    Abstract It is estimated that only aboutof young patients suffering from!activity limiting hip osteoarthritisOAchoose to undergo traditional hip replacement surgeryThis low percentage is attributed to the shortened projected lifetime of hip implants for active patients and the subsequent need for revision surgeries that are plagued with higher complication rates and overall decreased effectiveness ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Safety and Efficacy of a Titratable External Shunt

    SBC: CAMRAS VISION, INC.            Topic: W

    Glaucoma is a diverse group of chronic diseases that causes irreversible damage to the optic nerve and is a leading cause of blindness affectingmillion people worldwideIt is estimated thatinpeople who receivepropertreatment for glaucoma still experience loss of visionThe only proven method of treating glaucoma is to reduce the pressure in the eyeIntraocular PressureIOPAdvanced glaucoma must achiev ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. SBIR Phase II: Ultrasonic Nanocoining for Creating Large, Low-Cost Arrays of Sub-Wavelength Features

    SBC: SMART MATERIAL SOLUTIONS INC            Topic: MN

    The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project will be in development of Ultrasonic Nanocoining - a new platform technology that is used to generate plastic films or glass panels that are anti-reflective, self-cleaning, or colored through structure. Such nano-structured surfaces can provide benefits for a wide array of commercial applicat ...

    SBIR Phase II 2017 National Science Foundation
  10. A D osteoarthritis model targeting patient populations with high risk genetic polymorphisms

    SBC: Cytex Therapeutics, Inc.            Topic: NIAMS

    Abstract Osteoarthritis OA is a degenerative joint disease that affects an estimated million adults in the United States and results in an economic burden of over $ billion per year Although the burden of OA is immense current non surgical treatments are only palliative and no disease modifying OA drugs DMOADs presently exist to address the problem This lack of success in identifying ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government